期刊
TRENDS IN PHARMACOLOGICAL SCIENCES
卷 35, 期 2, 页码 103-109出版社
ELSEVIER SCIENCE LONDON
DOI: 10.1016/j.tips.2013.11.007
关键词
-
资金
- NCI NIH HHS [U01 CA176058, R01 CA140545] Funding Source: Medline
The canonical WNT pathway regulates the stability of the proto-oncogene p-catenin and is aberrantly activated in many cancer types. Studies in a wide range of experimental models confirm that p-catenin activity is required for tumor initiation in cancers where this pathway is deregulated. However, to date this pathway has proven to be challenging to target therapeutically. Moreover, several lines of evidence suggest that other components and regulators of I3-catenin exist. Here we will describe recent structural and functional studies describing genomic alterations and new regulators of 13-catenin that lead to aberrant activation of the WNT/I3-catenin pathway. These findings provide new insights into the biology of WNT/p-catenin signaling and suggest potential therapeutic opportunities.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据